David Taylor

43.2k total citations · 4 hit papers
879 papers, 26.2k citations indexed

About

David Taylor is a scholar working on Psychiatry and Mental health, Molecular Biology and Clinical Psychology. According to data from OpenAlex, David Taylor has authored 879 papers receiving a total of 26.2k indexed citations (citations by other indexed papers that have themselves been cited), including 297 papers in Psychiatry and Mental health, 121 papers in Molecular Biology and 84 papers in Clinical Psychology. Recurrent topics in David Taylor's work include Schizophrenia research and treatment (244 papers), Bipolar Disorder and Treatment (70 papers) and Treatment of Major Depression (68 papers). David Taylor is often cited by papers focused on Schizophrenia research and treatment (244 papers), Bipolar Disorder and Treatment (70 papers) and Treatment of Major Depression (68 papers). David Taylor collaborates with scholars based in United Kingdom, United States and Germany. David Taylor's co-authors include Carol Paton, Shubhra Mace, Eromona Whiskey, Robyn McAskill, Allan H. Young, Corina Young, Delia Bishara, Thomas R. E. Barnes, Mark Horowitz and Jimmi Nielsen and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

David Taylor

845 papers receiving 24.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

2016 1.0k citations David Taylor et al. profile →
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

2017 646 citations Stephen Pilling, David Taylor et al. profile →
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

2015 481 citations Allan H. Young, David Taylor et al. Journal of Psychopharmacology profile →
The Maudsley Prescribing Guidelines in Psychiatry

2021 327 citations David Taylor, Allan H. Young et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Taylor	8.1k	4.6k	3.8k	2.8k	2.1k	879	26.2k
Robert C. Young	10.1k 1.2×	4.6k 1.0×	2.6k 0.7×	2.0k 0.7×	1.7k 0.8×	385	34.7k
Siegfried Kasper	10.1k 1.2×	4.6k 1.0×	5.0k 1.3×	8.0k 2.9×	5.1k 2.4×	1.0k	34.8k
Abraham Weizman	9.2k 1.1×	5.3k 1.2×	6.3k 1.7×	2.4k 0.9×	4.7k 2.2×	981	28.4k
Andrew H. Miller	5.6k 0.7×	4.2k 0.9×	4.2k 1.1×	2.5k 0.9×	1.8k 0.9×	345	43.6k
John M. Davis	16.0k 2.0×	6.1k 1.3×	5.4k 1.4×	4.0k 1.4×	4.6k 2.2×	626	37.2k
John J. McGrath	12.5k 1.5×	3.8k 0.8×	6.5k 1.7×	1.3k 0.5×	2.1k 1.0×	579	36.3k
Paolo Brambilla	6.7k 0.8×	1.5k 0.3×	2.6k 0.7×	1.3k 0.5×	1.2k 0.6×	625	21.0k
Jari Tiihonen	8.8k 1.1×	1.6k 0.4×	5.3k 1.4×	2.0k 0.7×	3.7k 1.8×	563	19.9k
David A. Williams	6.7k 0.8×	4.9k 1.1×	1.3k 0.4×	7.2k 2.6×	1.8k 0.8×	614	26.6k
Robert Stewart	8.1k 1.0×	3.0k 0.7×	5.6k 1.5×	1.5k 0.5×	899 0.4×	848	30.2k

Countries citing papers authored by David Taylor

Since Specialization

Citations

This map shows the geographic impact of David Taylor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Taylor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Taylor more than expected).

Fields of papers citing papers by David Taylor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Taylor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Taylor. The network helps show where David Taylor may publish in the future.

Co-authorship network of co-authors of David Taylor

This figure shows the co-authorship network connecting the top 25 collaborators of David Taylor. A scholar is included among the top collaborators of David Taylor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Taylor. David Taylor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Horowitz, Mark, James O’Neill, Fabrice Berna, & David Taylor. (2025). Not So Hasty: The Effect of Tapering Speed on Relapse May Still Be Important. Schizophrenia Bulletin.

Taylor, David, et al.. (2025). The Safety of 12‐Weekly Monitoring of Neutrophil Count in Long‐Term Clozapine Patients. Acta Psychiatrica Scandinavica. 152(3). 187–192. 3 indexed citations

Iqbal, R., et al.. (2025). Decompression of gas-saturated solutions does not reveal bulk nanobubbles. Cell Reports Physical Science. 6(6). 102611–102611.

Andrés, Damián de, et al.. (2025). Efficacy of Dienogest Versus GnRH Agonists After Endometriosis Surgery: A Systematic Review and Meta-Analysis. Journal of Minimally Invasive Gynecology. 33(4). 391–402. 1 indexed citations

Taylor, David, et al.. (2024). Genetic identification of undiagnosed benign ethnic neutropenia in patients receiving clozapine treatment. The British Journal of Psychiatry. 227(2). 533–537. 1 indexed citations

Taylor, David, Ana Catalán, Edward Chesney, et al.. (2023). Point of care assay for blood aripiprazole concentrations: development, validation and utility. The British Journal of Psychiatry. 223(2). 389–393. 1 indexed citations

Chan, Adrienne Y L, Tiantian Ma, Wallis C. Y. Lau, et al.. (2023). Attention-deficit/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study. EClinicalMedicine. 58. 101780–101780. 34 indexed citations

Reilly, Thomas J., et al.. (2022). Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials. Journal of Psychopharmacology. 37(3). 261–267. 12 indexed citations

Bishara, Delia, Gayan Perera, Daniel Harwood, et al.. (2020). The anticholinergic effect on cognition (AEC) scale—Associations with mortality, hospitalisation and cognitive decline following dementia diagnosis. International Journal of Geriatric Psychiatry. 35(9). 1069–1077. 20 indexed citations

10.

Fox, T, et al.. (2020). Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation. SHILAP Revista de lepidopterología. 10. 3627464831–3627464831. 3 indexed citations

11.

Davies, Cathy, Yannis Paloyelis, Grazia Rutigliano, et al.. (2019). Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. Neuropsychopharmacology. 44(7). 1300–1309. 23 indexed citations

12.

Kadra-Scalzo, Giouliana, Johnny Downs, Hitesh Shetty, et al.. (2019). Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine. Journal of Psychopharmacology. 33(4). 449–458. 22 indexed citations

13.

Metrebian, Nicola, Tim Weaver, Stephen Pilling, et al.. (2019). Telephone delivered incentives for encouraging adherence to supervised methadone consumption (TIES): Study protocol for a feasibility study for an RCT of clinical and cost effectiveness. Contemporary Clinical Trials Communications. 17. 100506–100506. 5 indexed citations

14.

Kadra-Scalzo, Giouliana, Robert Stewart, Hitesh Shetty, et al.. (2018). Long‐term antipsychotic polypharmacy prescribing in secondary mental health care and the risk of mortality. Acta Psychiatrica Scandinavica. 138(2). 123–132. 25 indexed citations

15.

Nikolova, Viktoriya L., et al.. (2018). Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting. Journal of Psychopharmacology. 32(4). 408–415. 14 indexed citations

16.

Connolly, Anne, David Taylor, Anna Sparshatt, & Victoria Cornelius. (2011). Antipsychotic prescribing in Black and White hospitalised patients. Journal of Psychopharmacology. 25(5). 704–709. 12 indexed citations

17.

Luthi‐Carter, Ruth, David Taylor, Judit Pallos, et al.. (2010). SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences. 107(17). 7927–7932. 263 indexed citations

18.

Taylor, David, et al.. (2009). Risperidone long‐acting injection: a 6‐year mirror‐image study of healthcare resource use. Acta Psychiatrica Scandinavica. 120(2). 97–101. 28 indexed citations

19.

Baker, Gary A., et al.. (2007). A COMMUNICATION MODEL FOR VIRTUAL COLLABORATION. Issues in Information Systems. 1 indexed citations

20.

Parízek, J, J. C. Boursnell, M. F. HAY, A Babický, & David Taylor. (1966). ZINC IN THE MATURING RAT TESTIS. Reproduction. 12(3). 501–507. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact